Schering Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SCHERING, and what generic and branded alternatives to SCHERING drugs are available?
SCHERING has one hundred and one approved drugs.
Drugs and US Patents for Schering
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Schering | TRILAFON | perphenazine | INJECTABLE;INJECTION | 011213-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
Schering | NORMODYNE | labetalol hydrochloride | TABLET;ORAL | 018687-001 | Aug 31, 1987 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
Schering | DIPROSONE | betamethasone dipropionate | OINTMENT;TOPICAL | 017691-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
Schering Plough | IMDUR | isosorbide mononitrate | TABLET, EXTENDED RELEASE;ORAL | 020225-003 | Mar 30, 1995 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Schering
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Schering | NORMOZIDE | hydrochlorothiazide; labetalol hydrochloride | TABLET;ORAL | 019046-003 | Apr 6, 1987 | 4,012,444 | ⤷ Subscribe |
Schering Plough | LOTRIMIN | clotrimazole | CREAM;TOPICAL | 017619-001 | Approved Prior to Jan 1, 1982 | 3,660,577 | ⤷ Subscribe |
Schering | NORMODYNE | labetalol hydrochloride | TABLET;ORAL | 018687-002 | Aug 1, 1984 | 4,012,444 | ⤷ Subscribe |
Schering | NORMODYNE | labetalol hydrochloride | TABLET;ORAL | 018687-003 | Aug 1, 1984 | 4,066,755 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SCHERING drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Oral Suspension | 40 mg/mL | ➤ Subscribe | 2011-02-28 |
➤ Subscribe | Injection | 18 mg/mL, 16.7 mL vials | ➤ Subscribe | 2015-11-24 |
➤ Subscribe | Delayed-release Tablets | 100 mg | ➤ Subscribe | 2014-06-16 |
Similar Applicant Names
Here is a list of applicants with similar names.